Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Trial pipeline

Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.

Free access · No subscription for research tools or data exports

Filter the development pipeline

Reset

12 trials match this view; 18 reported facilities; 18 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 622 across 12 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

20131
20211
20221
20241
20253
20264
20271

Current indexed registry status

Not yet recruiting4
Completed4
Recruiting3
Unknown status1

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Milestones to investigate

The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.

For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.

Matching trial records

12 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT01988311

Psilocybin · Hallucinogens · Pharmacologic Actions · Central Nervous System Agents · Therapeutic Uses · Psychotropic Drugs
Johns Hopkins University

PHASE1

Completed

Registry updated 2014-05-20

10

ESTIMATED

2013-05
2014-01
2014-05
Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin

NCT04501653

Psilocybin
Washington University School of Medicine

EARLY_PHASE1

Completed

Registry updated 2025-10-31

11

ACTUAL

2021-06-01
2023-03-19
2023-03-19
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study

NCT04950608

Hospice · Psilocybin · Demoralization · Terminal Illness · Cancer-related Problem/Condition · Psychotherapy · Terminal Cancer · Cancer Terminal
Yvan Beaussant, MD, MSci

PHASE2

Completed

Registry updated 2026-02-17

15

ACTUAL

2022-03-09
2024-07-27
2025-12-31
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures

NCT06647056

Psychogenic Nonepileptic Seizures · Psilocybin
Centre Hospitalier Universitaire de Nīmes

NA

Completed

Registry updated 2025-08-21

4

ACTUAL

2024-12-19
2025-01-03
2025-05-22
Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders

NCT06471959

Psilocybin · Psychotherapy, Group
Empower Research Inc

PHASE1, PHASE2

Unknown status

Registry updated 2024-06-24

32

ESTIMATED

2025-01-01
2025-07-01
2025-09-01
Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

NCT06692192

Psilocybin
University of Wisconsin, Madison

PHASE1

Recruiting

Registry updated 2026-11-06

60

ESTIMATED

2025-08-07
2027-12
2027-12
PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NCT07180108

Psilocybin · Music Intervention
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-15

100

ESTIMATED

2025-08-12
2028-06
2028-08
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.

NCT07433452

Healthy Participants · Placebo - Control · Psilocybin
Gabriella Gobbi

PHASE1

Not yet recruiting

Registry updated 2026-02-25

50

ESTIMATED

2026-09-01
2028-09-01
2029-09-01
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder

NCT07566104

Depression - Major Depressive Disorder · Psilocybin · Cognitive Behavioral Therapy
University of California, Los Angeles

PHASE2

Not yet recruiting

Registry updated 2026-05-04

30

ESTIMATED

2027-01
2028-12
2028-12
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

NCT07227909

Psilocybin · Neuropathy
M.D. Anderson Cancer Center

PHASE2

Not yet recruiting

Registry updated 2026-11-12

90

ESTIMATED

2026-11-04
2029-01-31
2031-01-31
Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes

NCT07306364

Chronic Low Back Pain (CLBP) · Physical Therapy · Psilocybin
Yale University

PHASE2

Not yet recruiting

Registry updated 2026-10-26

48

ESTIMATED

2026-12
2029-06
2029-06
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

NCT07638553

Alcohol Use Disorder · Depressive Sympotoms · Psilocybin
Centre Hospitalier Universitaire de Nīmes

PHASE3

Recruiting

Registry updated 2026-11-17

172

ESTIMATED

2026-06-30
2030-06
2030-06

Reported research facilities

Centre for Neurology StudiesSurrey, British Columbia, Canada · Coordinates available
CH Le VinatierBron, France · Coordinates available
CHU BesançonBesançon, France · Coordinates available
CHU BrestBrest, France · Coordinates available
CHU Saint-EtienneSaint-Priest, France · Coordinates available
CHU de BordeauxBordeaux, France · Coordinates available
CHU de NantesNantes, France · Coordinates available
CHU de NîmesNîmes, France · Coordinates available
CHU de Nîmes, Hôpital Universitaire CarémeauNîmes, France · Coordinates available
Centre Hospitalier de la Côte BasqueBayonne, France · Coordinates available
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical CenterBaltimore, Maryland, United States · Coordinates available
Care DimensionsDanvers, Massachusetts, United States · Coordinates available
Center for Psychedelics and Consciousness Research in the Behavioral Biology Research CenterBaltimore, Maryland, United States · Coordinates available
Connecticut Mental Health CenterNew Haven, Connecticut, United States · Coordinates available
MD Anderson Cancer CenterHouston, Texas, United States · Coordinates available
UCLA Semel InstituteLos Angeles, California, United States · Coordinates available
UW School of Medicine and Public HealthMadison, Wisconsin, United States · Coordinates available
Washington UniversitySt Louis, Missouri, United States · Coordinates available

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.